Glutamine prevents gastric oxidative stress in an animal model of portal hypertension gastropathy

Annals of Hepatology

Volumn 10, Issue 4, 2011, Pages 531-539

  Marques, Camila ^a   Mauriz, José L ^d   Simonetto, Douglas ^b   Marroni, Claudio A ^b   Tuñon, María J ^d   González Gallego, Javier ^d   Marrón, Norma P ^a,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^c UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^d UNIVERSITY OF LEÓN   (Spain)

Author keywords

Glutamine; Nitric oxide; Portal hypertension

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CATALASE; GLUTAMINE; GLUTATHIONE PEROXIDASE; NITRIC OXIDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHEMOLUMINESCENCE; CONTROLLED STUDY; HISTOPATHOLOGY; MALE; NONHUMAN; OXIDATIVE STRESS; PORTAL HYPERTENSION; PORTAL HYPERTENSION GASTROPATHY; PORTAL VEIN BLOOD PRESSURE; RAT; STOMACH DISEASE; VEIN LIGATION;

EID: 80052866449     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31522-4     Document Type: Article

References (50)

1. Rodríguez-Vilarrupla A, Fernández M, Bosch J, García-Pagán JC. Current concepts on the pathophysiology of portal hypertension. Ann Hepatol 2007; 6: 28-36.
2. Thuluvath PJ, Yoo HY. Portal hypertensive gastropathy. Am J Gastroenterol 2002; 97: 2973-8.
3. Moreira AJ, Fraga C, Alonso M, Collado PS, Zetller C, Marroni C, et al. Quercetin prevents oxidative stress and NFkappaB activation in gastric mucosa of portal hypertensive rats. Biochem Pharmacol 2004; 68: 1939-46.
4. Vigneri S, Termini R, Piraino A, Scialabba A, Pisciotta G, Fontana N. The stomach in liver cirrhosis. Endoscopic, morphological, and clinical correlations. Gastroenterology 1991; 101: 472-8.
5. Carpinelli L, Primignani M, Preatoni P, Angeli P, Battaglia G, Beretta L, et al. Portal hypertensive gastropathy: reproducibility of a classification, prevalence of elementary lesions, sensitivity and specificity in the diagnosis of cirrhosis of the liver. A NIEC multicentre study. New Italian Endoscopic Club. Ital J Gastroenterol Hepatol 1997; 29: 533-40.
6. Pique JM. Portal hypertensive gastropathy. Baillieres Clin Gastroenterol 1997; 11: 257-70.
7. Sarin SK, Sreenivas DV, Lahoti D, Saraya A. Factors influencing development of portal hypertensive gastropathy in patients with portal hypertension. Gastroenterology 1992; 102: 994-9.
8. Amarapurkar DN, Dhawan PS, Chopra K, Shankaran K, Kalro RH. Stomach in portal hypertension. J Assoc Physicians India 1993; 41: 638-40.
9. Zaman A, Hapke R, Flora K, Rosen H, Benner K. Prevalence of upper and lower gastrointestinal tract findings in liver transplant candidates undergoing screening endoscopic evaluation. Am J Gastroenterol 1999; 94: 895-99.
10. Urata J, Yamashita Y, Tsuchigame T, Hatanaka Y, Matsukawa T, Sumi S, et al. The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy. J Gastroenterol Hepatol 1998; 13: 1061-7.
11. Marley R, Holt S, Fernando B, Harry D, Anand R, Goodier D, et al. Lipoic acid prevents development of the hyperdynamic circulation in anesthetized rats with biliary cirrhosis. Hepatology 1999; 29: 1358-63.
12. Seckin Y, Harputluoglu MM, Batcioglu K, Karincaoglu M, Yildirim B, Oner RI, et al. Gastric tissue oxidative changes in portal hypertension and cirrhosis. Dig Dis Sci 2007; 52: 1154-8.
13. Prieto I, Jiménez F, Aller MA, Nava MP, Vara E, Garcia C, et al. Tumor necrosis factor-alpha, interleukin-1beta and nitric oxide: induction of liver megamitochondria in prehepatic portal hypertensive rats. World J Surg 2005; 29: 903-38.
14. Ohta M, Yamaguchi S, Gotoh N, Tomikawa M. Pathogenesis of portal hypertensive gastropathy: a clinical and experimental review. Surgery 2002; 131: S165-S170.
15. De Aguilar-Nascimento JE, Caporossi C, Dock-Nascimento DB, de Arruda IS, Moreno K, Moreno W. Oral glutamine in addition to parenteral nutrition improves mortality and the healing of high-output intestinal fistulas. Nutr Hosp 2007; 22: 672-6.
16. Fontana Gallego L, Sáez Lara MJ, Santisteban Bailón R, Gil Hernández A. Nitrogenous compounds of interest in clinical nutrition. Nutr Hosp 2006; 21: 14-27.
17. Powell-Tuck J. Nutritional interventions in critical illness. Proc Nutr Soc 2007; 66: 16-24.
18. Shive W, Snider RN, DuBilier B, Rude JC, Clarke GE, Ravel JO. Glutamine treatment of peptic ulcer. Texas State J Med 1957; 53: 840-2.
19. Rizzi CF, Mauriz JL, Freitas Corrêa DS, Moreira AJ, Zettler CG, Filippin LI, et al. Effects of low-level laser therapy (LLLT) on the nuclear factor (NF)-kappaB signaling pathway in traumatized muscle. Lasers Surg Med 2006; 38: 704-13.
20. Cattell V, Cook T, Moncada S. Glomeruli synthesise nitrite in experimental nephrotoxic nephritis. Kidney Int 1990; 38: 1056-60.
21. Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 247: 3170-5.
22. Flohé L, Günzler WA. Assays of glutathione peroxidase. Methods Enzymol 1984; 105: 114.
23. Aebi H. Catalase in vitro. Methods Enzymol 1984; 105: 121-6.
24. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Gastrointest Liver Physiol 1985; 248: G618-G625.
25. Abraldes JG, Pasarín M, García-Pagán JC. Animal models of portal hypertension. World J Gastroenterol 2006; 12: 6577-84.
26. Sabra R, Shuman S. Influence of phenobarbital on changes in Na handling, hemodynamics and liver function due to portal vein ligation in rats. Eur J Pharmacol 2001; 413: 287-94.
27. Yokoyama Y, Baveja R, Sonin N, Clemens MG, Zhang JX. Hepatic neovascularization after partial portal vein ligation: novel mechanism of chronic regulation of blood flow. Am J Physiol Gastrointest Liver Physiol 2001; 280: G21-G31.
28. Bayraktar Y, Balkanci F, Uzunalimoglu B, Gokoz A, Koseoglu T, Batman F, et al. Is portal hypertension due to liver cirrhosis a major factor in the development of portal hypertensive gastropathy? Am J Gastroenterol 1996; 91: 554-8.
29. Panes J, Casadevall M, Fernandez M, Pique JM, Bosch J, Casamitjana R, et al. Gastric microcirculatory changes of portal-hypertensive rats can be attenuated by long-term estrogen-progestagen treatment. Hepatology 1994; 20: 1261-70.
30. Hung CR, Neu SL. Acid-induced gastric damage in rats is aggravated by starvation and prevented by several nutrients. J Nutr 1997; 127: 630-6.
31. Elia M, Lunn PG. The use of glutamine in the treatment of gastrointestinal disorders in man. Nutrition 1997; 13: 743-7.
32. Mauriz JL, Linares P, Macias RI, Jorquera F, Honrado E, Olcoz JL, et al. TNP-470 inhibits oxidative stress, nitric oxide production and nuclear factor kappa B activation in a rat model of hepatocellular carcinoma. Free Radic Res 2003; 37: 841-8.
33. Villegas I, Martín MJ, La Casa C, Motilva V, Alarcon de la Lastra C. Effects of oxicam inhibitors of ciclooxygenase on oxidative stress generation in rat gastric mucosa. A comparative study. Free Radical Res 2002; 36: 769-77.
34. Fernando B, Marley R, Holt S, Anand R, Harry D, Sanderson P, et al. N-acetylcysteine prevents development of the hyperdynamic circulation in the portal hypertensive rats. Hepatology 1998; 28: 689-94.
35. Sido B, Seel C, Hochlehnert A, Breitkreutz R, Dröge W. Low intestinal glutamine level and low glutaminase activity in Crohn's disease: a rational for glutamine supplementation? Dig Dis Sci 2006; 51: 2170-9.
36. Deger C, Erbil Y, Giris M, Yanik BT, Tunca F, Olgaç V, et al. The effect of glutamine on pancreatic damage in TNBSinduced colitis. Dig Dis Sci 2006; 51: 1841-6.
37. Kinjo N, et al. Significance of ERK nitration in portal hypertensive gastropathy and its therapeutic implications. Am J Physiol Gastrointest Liver Physiol 2008; 295: G1016-G1024.
38. Kawanaka H, et al. Defective mitogenactivated protein kinase (ERK2) signaling in gastric mucosa of portal hypertensive rats: potential therapeutic implications. Hepatology 2001; 34: 990-999.
39. Curi R, Lagranha CJ, Doi SQ, Sellitti DF, Procopio J, Pithon-Curi TC, et al. Molecular mechanisms of glutamine action. J Cell Physiol 2005; 204: 392-401.
40. Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res 1994; 31: 131-43.
41. Kawanaka H, et al. Activation of eNOS in Rat Portal Hypertensive Gastric Mucosa Is Mediated by TNF-a Via the PI 3-Kinase- Akt Signaling Pathway. Hepatology 2002; 35: 393-402.
42. Kawanaka H, Portal hypertensive gastric mucosa has reduced activation of MAP kinase (ERK2) in response to alcohol injury: a key to impaired healing? FASEB J 2001; 15(3): 574-6.
43. Lopez-Belmonte J, Whittle BJR, Moncada S. The actions of nitric oxide donors in the prevention or induction of injury to the rat gastric mucosa. Br J Pharmacol 1993; 108: 73-8.
44. Ohta M, Tanoue K, Tarnawski AS, Pai R, Itani RM, Sander FC, et al. Overexpressed nitric oxide synthase in portalhypertensive stomach of rat: a key to increased susceptibility to damage? Gastroenterology 1997; 112: 1920-30.
45. Hsieh JS, Wang JY, Lin SR, Lian ST, Chen FM, Hsieh MC, et al. Overexpression of inducible nitric oxide synthase in gastric mucosa of rats with portal hypertension: correlation with gastric mucosal damage. J Surg Res 2003; 115: 24-32.
46. Pollock JS, Forstermann U, Mitchell JA, Warner TD, Schmidt HH, Nakane M, Murad F. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991; 88: 10480-4.
47. Hecker M, Sessa WC, Harris HJ, Anggard EE, Vane JR. The metabolism of L-arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: cultured endothelial cells recycle L-citrulline to L-arginine. Proc Natl Acad Sci USA 1990; 87: 8612-6.
48. Tarnawski AS, Tomikawa M, Kawanaka H, Sugimachi K, Sarfeh IJ. Increased oxygen free radicals, nitrotyrosine and enhanced lipid peroxydation in portal hypertensive gastric mucosa: A key to increased susceptibility to injury. Gastroenterology 1999; 116: A1282.
49. Fillmann H, Kretzmann NA, San-Miguel B, Llesuy S, Marroni N, González-Gallego J, et al. Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. Toxicology 2007; 236: 217-26.
50. Joe B, Lokesh BR. Studies on the inactivation of superoxide dismutase activity by nitric oxide from rat peritoneal macrophages. Mol Cell Biochem 1997; 168: 87-93.